Rainer Schulz - Selected Publications#

1. Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, Davidson SM, Dobrev D, Gersh BJ, Heusch G, Lecour S, Ruiz-Meana M, Zuurbier CJ, Hausenloy DJ, Schulz R. Interaction of cardiovascular non-modifiable risk factors, comorbidities and comedications with is.hemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning. Pharmacological Reviews 75:159-216, 2023, dx.doi.org/10.1124/pharmrev.121.000348

2. Heusch G, Bøtker HE, Ferdinandy P, Schulz R. Primordial non-responsiveness: a neglected obstacle to cardioprotection. Eur Heart J. 2023 Mar 21:ehad160. doi: 10.1093/eurheartj/ ehad160. Online ahead of print.

3. Schulz R, Heusch G. Targeted Mito- and Cardioprotection by Malonate. Circ Res 131:542-544, 2022, doi: 10.1161/CIRCRESAHA.122.321582.

4. De Smet MA, Lissoni A, Nezlobinsky T, Wang N, Dries E, Pérez-Hernández M, Lin X, Amoni M, Vervliet T, Witschas K, Rothenberg E, Bultynck G, Schulz R, Panfilov AV, Delmar M, Sipido KR, Leybaert L. Cx43 hemichannel microdomain signaling at the intercalated disc enhances cardiac excitability. J Clin Invest 131:e137752, 2021, doi: 10.1172/JCI137752.

5. Hirschhäuser Ch, Lissoni A, Görge PM, Lampe PD, Heger J, Schlüter KD, Leybaert L, Schulz R, Boengler K. Connexin 43 phosphorylation by casein kinase 1 is essential for the cardioprotection by ischemic preconditioning. Basic Res Cardiol. 2021 Mar 22;116(1):21. Doi: 10.1007/s00395-021-00861-z.

6. Andreadou I, Efentakis P, Frenis K, Daiber A, Schulz R.Thiol-based redox-active proteins as cardioprotective therapeutic agents in cardiovascular diseases. Basic Res Cardiol. 2021 Jul 17;116(1):44. doi: 10.1007/s00395-021-00885-5.

7. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, Varga ZV, Varró A, Schulz R. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart 40:1771-1777, 2019, doi: 10.1093/eurheartj/ehy365

8. Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG, Lima BHF, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S, Lima-Júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation 138:696-711, 2018, doi: 10.1161/CIRCULATIONAHA.117.030352.

9. Leybaert L, Lampe PD, Dhein S, Kwak BR, Ferdinandy P, Beyer EC, Laird DW, Naus CC, Green CR, Schulz R. Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications. Pharmacol Rev 69: 396-478, 2017, doi: 10.1124/pr.115.012062.

10. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66: 1142-1174, 2014, doi: 10.1124/pr.113.008300.

Google Scholar: h-Index 97
Scopus: h-Index 84